Discovery Phase Clause Samples

Discovery Phase. The discovery phase is typically a phone or web interview that typically lasts a couple of hours Preparing Data is a key component of the service and requires client input, but the consultant will take care of the rest! Setup workflow to meet use-cases and begin PM training User training sessions by user role or function and typically last up to 90 minutes for up to 10-15 users After data is loaded, the account configured, and users are trained the system is ready to roll-out

Discovery Phase. In the discovery phase, there is insufficient information for the parties to reach a final contract with in-depth product specifications, final budget and schedule, production milestones, deliverables, etc. SolutionX and Client work together to reach an interim agreement or letter of intent, based on the high-level overview of the concept document. This letter of intent allows the parties to move forward with creating the all-inclusive scope document and to derive from it a final schedule and final budget which will lead to a final contract.

Discovery Phase. Defining the User Journey and key elements of the Register website

Discovery Phase. (a) ABX shall provide AZ with reasonable research quantities of each Research Antibody as specified in the applicable Research Program Work Plan, at ABX’s sole cost and expense, in order for AZ to assess such Antibody and perform its activities under the applicable Research Program and exercise its rights under Article 2. Notwithstanding the foregoing, AZ shall have the right to reasonably request additional research quantities of an Antibody, beyond those quantities set forth in the Research Program Work Plan, for the sole purpose of performing activities outside of the Research Programs that are directed towards designating a Candidate Drug, but not for the purpose of furthering any other AZ activities. If AZ reasonably requests additional research quantities of an Antibody for such purpose, then ABX, at AZ’s sole cost and expense, shall be responsible for manufacturing and supplying such additional research quantities for such purpose. ABX, at its sole cost and expense, shall be responsible for such Antibody scale up activities as are necessary to complete the activities set forth in the Research Programs. If AZ requests additional quantities of any Antibodies as permitted under this Section 7.2.1(a) and ABX does not have sufficient uncommitted quantities available, ABX shall, at its sole cost and expense, provide AZ with the cell line for each such Antibody to enable AZ to produce such Antibody for such purposes. (b) Except as otherwise described in Section 7.2.1(a) and as provided in Sections 7.5, 7.6 and 7.13, ABX, at AZ’s sole cost and expense subject to Section 7.13, shall be responsible for all process development and manufacturing activities (including cell line development and scale up) required to be conducted, prior to the designation of a Candidate Drug, in accordance with the Process Science/Clinical Manufacture Agreement.

Discovery Phase. A. Development of Design Criteria. TREKK will develop a design criteria memo.

Discovery Phase. 7 1. This Agreement shall govern all documents and electronically stored information 8 (“ESI”), the information contained therein, and all other information produced or disclosed 9 during the Proceeding whether revealed in a document, deposition, other testimony, discovery 10 response or otherwise, by any party, including any non-party, in this Proceeding (the “Producing 11 Party”) to any other party, including any non-party, when same is designated with the procedures 12 set forth herein. This Agreement is binding upon the parties to the Proceeding, including their 13 respective corporate parents, subsidiaries, and affiliates, as well as their respective attorneys, 14 agents, representatives, officers, and employees and others as set forth in this Agreement. This 15 Agreement is also binding on and applies to all non-parties who either produce or receive 16 documents or information in connection with this Proceeding. 17 2. A Producing Party may designate as “CONFIDENTIAL” any material the 18 producing party believes in good faith constitutes or discloses information or that qualifies for 19 protection pursuant to the Federal Rules of Civil Procedure, specifically information that is trade 20 secret or other confidential research, development, or commercial information, and materials 21 that are deemed confidential under Federal Drug Administration ("FDA") regulations and Health 22 Insurance Portability and Accountability Act ("HIPAA") statutes and/or regulations. 23 3. Confidential information may be further designated as “HIGHLY 24 CONFIDENTIAL” if the Defendant produces materials that it believes in good faith would, if 25 disclosed, cause substantial economic harm to the competitive position of the entity from which 26 the information was obtained because it relates to research and development material on a new 27 product that has not been approved or cleared by the FDA or a similar regulatory body or reflects 28 a party’s price competitiveness in the market or marketing business strategies of a party 1 concerning a current or new product. The Plaintiff will inform the Producing Party of its intent 2 to disclose such information to any individual who is currently, or who at any time during the 3 pendency of this litigation becomes, a consultant to a competitor of the Producing Party in the 4 pelvic mesh business, or is a consultant to an entity actively investigating entering such business, 5 and Plaintiff will follow the procedures for disclosure of s...

Discovery Phase. SFRTA and Genfare will work with each Participating Agency to gather information regarding: • Technical access via API(s) and/or other mechanisms to each Participating Agency's AFCS back office. • Fare policies, including transfer and qualified discount requirements • Each Participating Agency's desired terms and conditions for use of the app and the sale of their fare products • General and agency-specific requirements for Payment Card Industry Data Security Standard (PCI) compliance and user data protection. • Technical Mechanisms for qualified discount and full fare customer accounts • Customer service procedures and mechanisms • Current and desired reporting functions • Each Participating Agency's list of participating project team members • Each Participating Agency's list of app implementation / support team members • Roles and responsibilities for each Participating Agency's implementation / support team members. The Discovery Phase will produce the following products for the review and approval of each Participating Agency: • Summary documents containing all information gleaned from the discovery phase for each Participating Agency, including fare policies, desired terms and conditions for use of the app and the sale of their fare products and general and agency-specific requirements for Payment Card Industry Data Security Standard (PCI) compliance and user data protection. • A document describing the technical functions and agency workflows associated with each Participating Agency's administration of their connection to the app. • A document, complete with screen mock-ups to capture the customer experience proposed in the app design. • A User Acceptance Testing (UAT) plan document • A tentative schedule for the project phases that follow. • A contact list for each Participating Agency's participating project team members • A contact list for each Participating Agency's participating implementation / support team members • Documents delineating roles and responsibilities for each Participating Agency's implementation / support team members Genfare and the Genfare subcontractors will develop the app solution component for each Participating Agency in accordance with the approved discovery and design documents developed during the Discovery Phase. Each Participating Agency will provide timely feedback as required during this phase. Following development, SFRTA and Genfare will update the tentative schedule developed as a product of the Discovery Pha...

Discovery Phase. The Discovery Phase is completed when the Assessment Meeting is held. It is expected that the Assessment Meeting will be conducted two (2) weeks after the Introductory Meeting is held (five weeks after the license agreement is executed). The objective of this phase is to compile a complete, documented reference base to be used to define, configure and setup your QMACS(TM) system for optimal performance in your business environment. Incomplete or inaccurate information may result in a faulty or failed project. QCSI DataCenter has the following responsibilities during the Discovery Phase: Review Discovery Documents Conduct Assessment Meetings ASSESSMENT MEETINGS The Assessment Meetings include a Technical Assessment and a Business Assessment. QCSI DataCenter staff will chair each of these meetings and full participation from the IMPACT Action Team is required. These meetings will be conducted at your facility and will be held after all discovery documents are completed and have been reviewed by your DataCenter IMPACT team members. Be sure that all discovery documents are delivered to your DataCenter team at least five (5) working days before the Assessment meeting. The TECHNICAL ASSESSMENT MEETING is chaired by the DataCenter Technical Analyst assigned to your IMPACT project. Your assigned DataCenter IMPACT Database Analyst and Systems and Network Analyst will participate. This meeting should be preceded by a tour of your organization with special emphasis on your workstations. Approximately four (4) hours are required to complete this portion of the discovery process at your facility. The BUSINESS ASSESSMENT MEETING is chaired by the DataCenter Implementation Team Leader assigned to your DataCenter IMPACT project. Your IMPACT Project Manager and Professionals must participate. This meeting is dependent upon completion of the Business Analysis Questionnaire. If this document is not complete, and has been reviewed by the DataCenter Implementation Team Leader prior to the Business Assessment, this meeting will be rescheduled. This meeting should be preceded by a tour of your organization with special emphasis on the departments that will be using QMACS(TM). Your DataCenter IMPACT consultants will want to observe the following processes: Enrollment of a new member Addition of a provider or contract 12 (c)Quality Care Solutions, Inc. 02/03/99 26 Addition of a new benefit plan Changes to member, provider, contracts or benefit plan information Issuing and changing...

Discovery Phase. Provide LOCAL PUBLIC AGENCY with a data request list and work together to complete data requests • Initiate on‐boarding and site visit for Consultant team & perform key stakeholder interviews • Collate, itemize, and categorize inventory of available assets from LOCAL PUBLIC AGENCY and associated core assumptions • Leverage Consultant’s proprietary Sponsorship Intelligence Database to deliver Landscape Analysis and Sponsorship best practices report o Details of comparable key inventory o Marketplace deal analysis (i.e., deals of other properties in your market) o Latest sponsorship industry trends & best‐in‐class sponsorship case studies • Deliverable: Landscape Analysis • Identify and value assets needed to attract audiences • Provide strategic insights during project planning & architectural design • Prepare asset rate card with asset‐by‐asset FMV’s, reach, and quantities • Provide revenue projections for multiple commercial scenarios • Leverage sponsorship trends and brand expertise • Optimize sponsorship inventory under each commercial scenario • Deliverable: Scenario‐based revenue projections • Create a packaging strategy that maximizes revenue, inclusive of a custom sponsorship hierarchy with number of partners per tier & investment thresholds per tier • Create an optimized Naming Rights package • Define business rules & guidelines for packaging • Identify the most viable partnership categories & prospects • Deliver a fully customized go‐to‐market strategy • Deliverables: